How to Buy Guardant Health Stock
Guardant Health Inc
Guardant Health, Inc. , a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
Guardant Health stock last closed at $90.49, down 0.78% from the previous day, and has increased 152.48% in one year. It has overperformed other stocks in the Diagnostics & Research industry by 1.5 percentage points. Guardant Health stock is currently +148.87% from its 52-week low of $36.36, and -25.05% from its 52-week high of $120.74.
As of Mar 10, 2026, there are 131.17M shares of GH outstanding. The market capitalization of GH is $11.87B. In the past 24 hours, 1.34M GH shares were traded.
How to Buy Guardant Health Stock
Wondering how to invest in Guardant Health stock? Here's how.
- Decide where to buy Guardant Health stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you figure out where to buy Guardant Health stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Pick your method of payment and add your info.
- Analyze Guardant Health stock: The Guardant Health ticker symbol is GH. Is Guardant Health stock a good investment? Should you buy shares of GH? How do GH's underlying business fundamentals look? Do top analysts think Guardant Health is a good buy? Why has GH's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if GH is a good stock to buy).
- Execute your GH trade: Decide if you will purchase GH shares at the current market price or use a limit order to purchase GH stock at a given price.
- Keep an eye on your GH position: Create a watchlist to monitor your investment in Guardant Health shares.
Step 1: Decide where to buy Guardant Health stock
You will need a brokerage account to access the NASDAQ market and buy GH stock.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Tech to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked your brokerage, you need to fill out some personal info so you are able to invest in GH stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to create a new brokerage account.
- Submit your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've finished signing up on the best stock trading app, you need to deposit funds:
Check out the video below for more details depositing funds into your investment account.
Step 4: Analyze Guardant Health stock
After you have decided on the best place to buy Guardant Health stock, it's absolutely critical to analyze their stock prior to buying, so you actually wrap your head around the risk and opportunity.
Guardant Health quick stats
GH Overview
WallStreetZen was built to help everyday investors do better fundamental analysis.
You can see all of the due diligence checks on GH's stock page.
Is GH stock overvalued?
You can use many financial metrics, analyses, models, and charts to gauge GH's intrinsic value.
You can access additional valuation research on GH's stock here.
GH Financial Overview
Passed Health Checks:
- GH has cash burn of 233066000. It has sufficient cash and short-term investments to cover this for at least one year.
- GH has $1.31B in cash and short term investments. This is enough to cover its annual cash burn of $233.07M.
- There are more short-term assets than short-term liabilities on the GH balance sheet.
Failed Health Checks:
- Total GH debt is still negative.
- There are more long-term liabilities than short-term assets on the GH balance sheet.
- GH profit margin has gone up by 0.17 percentage points in the past year, but the company is still unprofitable.
- GH debt to equity ratio of -21.28 is negative.
Do Wall Street analysts think it's a good time to buy Guardant Health stock
Out of 17 Equities analysts who research GH, the consensus analyst rating on Guardant Health is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Latest GH Analyst Ratings
Dan Brennan, a top 18% analyst from TD Cowen maintains GH with a strong buy rating and raises their GH price target from $130.00 to $135.00, on Feb 20, 2026.
TD Cowen's Dan Brennan raised their price target on Guardant Health (NASDAQ: GH) by 3.8% from $130 to $135 on 2026/02/20. The analyst maintained their Strong Buy rating on the stock.
Guardant Health reported its Q4 and FY 2025 earnings.
Raising their price target, Brennan headlined that management provided "solid" FY 2026 guidance, "with Q4 top-line know, though true-ups more of a help."
The analyst said the highlight of the print was the 2026 Screening segment guidance, which included considerable investment in the sales force.
Earnings Report
Guardant Health reported:
For Q4 2025:
- Loss per share of $0.50, which missed the Zacks Consensus Estimate of $(0.42) but beat, by 19.4%, Q4 2024’s $(0.62).
- Revenue of $281.27M, which beat the Zacks Consensus Estimate by 0.47% and, by 39%, Q4 2024’s $201.81M.
For FY 2025:
- Loss per share of $1.82, compared to FY 2024’s loss of $2.01.
- Revenue of $982M, up 33% Y/Y.
For FY 2026, management guided:
- Revenue of $1.25B to $1.28B.
Co-founder & Co-CEO Helmy Eltoukhy commented: “We delivered an outstanding end to a great year, with Q4revenue growth of 39% Y/Y.
“Our progress in 2025 is a testament to our breakthrough innovation and best-in-class execution across our portfolio.
“We are uniquely positioned with scaled offerings spanning both therapy selection and monitoring, and the recent launch of Reveal for therapy response monitoring further strengthens our competitive moat.
“We look forward to another strong year ahead, supported by a diverse set of growth catalysts across our business.”
Co-founder & Co-CEO AmirAli Talasaz added, “Shield has become one of the most successful diagnostic launches, with meaningful volume and revenue generation in 2025 that exceeded our expectations.
“We are proud of the level of impact we have had to date, our commercial performance, and the strong operational foundations we’ve built to support the growing demand for Shield.
“We are excited to deliver another year of significant growth in 2026, fueled by our expanding commercial infrastructure and a pipeline of growth drivers in front of us.”
Brandon Couillard, a bottom 8% analyst from Wells Fargo maintains GH with a strong buy rating and raises their GH price target from $120.00 to $125.00, on Feb 20, 2026.
Daniel Arias, a top 18% analyst from Stifel Nicolaus maintains GH with a strong buy rating and raises their GH price target from $120.00 to $130.00, on Feb 20, 2026.
Daniel Markowitz, a bottom 13% analyst from Evercore ISI Group maintains GH with a hold rating and raises their GH price target from $105.00 to $110.00, on Feb 20, 2026.
Catherine Schulte, a top 15% analyst from Baird initiates coverage on GH with a buy rating and announces their GH price target of $120.00, on Feb 17, 2026.
You can dive deeper into what analysts are forecasting on the Guardant Health stock forecast page.
GH Momentum
GH Performance Numbers
Last year, GH revenue was $982.02M. In the past five year, GH's revenue has gone up by 27.92% per year. This was faster than the Diagnostics & Research industry average of 8.62%.
Find out more about GH's earnings and revenue performance here.
Who is buying/selling GH?
Over the past year, insiders at GH have sold more shares than they have bought.
Medina Manuel Hidalgo, Director of GH, was the latest GH insider to buy. They bought $32,550.00 worth of GH stock on Mar 6, 2026.
Research more about who owns GH stock here.
Does GH provide a stable income stream?
No, Guardant Health doesn't provide an income stream by paying out dividends.
What others are saying about GH
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Execute your GH trade
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific dollar amount limit, place a limit order.
Press the Open button and your broker will place the order.
If you need additional help investing in stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your GH position
Now that you own some GH shares, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to track your GH stock.
GH Feed
How to Buy Stock in Guardant Health
To summarize, here are the 6 steps you need to take to buy Guardant Health stock right now:
- Decide where to buy Guardant Health stock
- Open a brokerage account
- Deposit funds into your brokerage account
- Analyze Guardant Health stock
- Execute your GH trade
- Keep an eye on your GH position
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get updates on your investment in Guardant Health, add GH to your watchlist by clicking the button below.
Other "How To" Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.